vTv Therapeutics Inc (NASDAQ:VTVT) shares rose 8.2% during mid-day trading on Thursday after an insider bought additional shares in the company. The company traded as high as $1.50 and last traded at $1.59, approximately 19,497 shares were traded during trading. A decline of 98% from the average daily volume of 818,290 shares. The stock had previously closed at $1.47.
Specifically, major shareholder Ronald O. Perelman acquired 1,212,121 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The shares were purchased at an average price of $1.65 per share, for a total transaction of $1,999,999.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $1.38 per share, for a total transaction of $69,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 5,048,485 shares of company stock worth $8,265,500. 1.70% of the stock is owned by company insiders.
VTVT has been the topic of several research reports. Northland Securities reiterated a “buy” rating and set a $8.00 price objective on shares of vTv Therapeutics in a research note on Thursday, August 1st. ValuEngine lowered shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of vTv Therapeutics in a research note on Friday, August 16th.
The firm’s 50 day simple moving average is $1.34 and its 200 day simple moving average is $1.56. The company has a market cap of $73.62 million, a price-to-earnings ratio of -2.28 and a beta of -3.64.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.63 million. As a group, analysts expect that vTv Therapeutics Inc will post -0.53 EPS for the current fiscal year.
An institutional investor recently raised its position in vTv Therapeutics stock. BlackRock Inc. raised its position in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,031 shares of the biotechnology company’s stock after purchasing an additional 13,305 shares during the quarter. BlackRock Inc. owned about 0.12% of vTv Therapeutics worth $93,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.64% of the company’s stock.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Featured Article: Are all No-Load Funds Equal?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.